Surgical treatment of primary melanoma of the umbilicus with sentinel lymph node biopsy and plastic reconstruction: Case report and review of the literature

2011 ◽  
Vol 37 (3) ◽  
pp. 233-236 ◽  
Author(s):  
A. Zaccagna ◽  
D. Siatis ◽  
A. Pisacane ◽  
E. Giacone ◽  
F. Picciotto
Mastology ◽  
2020 ◽  
Vol 30 (Suppl 1) ◽  
Author(s):  
Flavio Rocha Gil ◽  
Mariane de Melo Silveira ◽  
Giovana Vilela Rocha ◽  
Plinio Resende de Melo

Introduction: Sentinel lymph node biopsy is indicated as gold standard in the surgical treatment of initial breast cancer, presenting as a more conservative approach and preventing total lymphadenectomy. Dyes or technetium radiopharmaceuticals can be used to identify the sentinel lymph node. The most used dyes for the identification of the sentinel lymph node are patent blue and isosulfan blue, and, in lower frequency, methylene blue. However, hypersensitivity reactions to blue dye have been described, estimating its prevalence in 0.6%‒2.7%. The clinical status that characterizes the allergic reaction to the dye can range from mild skin changes to the severe condition, with circulatory collapse. Objectives: To present a severe case of allergic reaction to patent blue in a patient submitted to surgical treatment for breast cancer. Method: This is a case report study based on the analysis of medical records and literature review. Case report: T.L.O.M, female, 49-year old woman, white, married, born in Patos de Minas, MG. Patient diagnosed with Breast cancer, T1N0A0, with indication for sentinel lymph node analysis with blue patent and segmental resection of the tumor. ASA 1 pre-anesthetic evaluation, without history of allergy. The patient was submitted to general inhalation anesthesia and subcutaneous injection in the left breast of 2ml of patent blue, followed by massage. During the anesthetic plan, after 40 minutes of surgery, the patient was hypotensive (40x20 mmHg), with low saturation (ETCO2 28), tachycardia (120 bpm), associated with bluish urticariform papules, and major edema in the ear lobes, being immediately assisted with adrenaline bolus, metaraminol, and decadron. The patient became stable, and it was possible to conclude the procedure. Then, she was referred to the intensive care unit, under sedation and intubated due to the risk of laryngospasm. She evolved hemodynamically stable, and was extubated without intercurrences. Conclusions: A severe anaphylactic reaction to patent blue can risk the life of a patient in an unpredictable manner. Considering this case, it is essential that the entire staff involved in the sentinel lymph node biopsy be aware of the possibility of a hypersensitive reaction to the dye, being prepared to recognize and immediately handle the possible repercussions.


2011 ◽  
Vol 30 (3) ◽  
pp. 171-173
Author(s):  
I. Lanchas Alfonso ◽  
M.B. Miguel Martínez ◽  
J.F. CuezvaGuzmán ◽  
P. Rupérez Arribas ◽  
S. Martínez Blanco ◽  
...  

Cancer ◽  
2006 ◽  
Vol 107 (11) ◽  
pp. 2647-2652 ◽  
Author(s):  
Christopher J. Gannon ◽  
Dennis L. Rousseau ◽  
Merrick I. Ross ◽  
Marcella M. Johnson ◽  
Jeffrey E. Lee ◽  
...  

Author(s):  
Vernon K. Sondak ◽  
Sandra L. Wong ◽  
Jeffrey E. Gershenwald ◽  
John F. Thompson

Sentinel lymph node biopsy (SLNB) was introduced in 1992 to allow histopathologic evaluation of the “sentinel” node, that is, the first node along the lymphatic drainage pathway from the primary melanoma. This procedure has less risk of complications than a complete lymphadenectomy, and if the sentinel node is uninvolved by tumor the likelihood a complete lymphadenectomy would find metastatic disease in that nodal basin is very low. SLNB is now widely used worldwide in the staging of melanoma as well as breast and Merkel cell carcinomas. SLNB provides safe, reliable staging for patients with clinically node-negative melanomas 1 mm or greater in thickness, with an acceptably low rate of failure in the sentinel node-negative basin. Evidence-based guidelines jointly produced by ASCO and the Society of Surgical Oncology (SSO) recommend SLNB for patients with intermediate-thickness melanomas and also state that SLNB may be recommended for patients with thick melanomas. Major remaining areas of uncertainty include the indications for SLNB in patients with thin melanomas, pediatric patients, and patients with atypical melanocytic neoplasms; the optimal radiotracers and dyes for lymphatic mapping; and the necessity of complete lymphadenectomy in all sentinel node-positive patients.


2004 ◽  
Vol 43 (1) ◽  
pp. 60-63 ◽  
Author(s):  
Derya Özçelik ◽  
Soner Tatlıdede ◽  
Semra Hacıkerim ◽  
Kemal Uğurlu ◽  
Murat Atay

Sign in / Sign up

Export Citation Format

Share Document